FEATURES

DESCRIPTION

Also known as RASF5_HUMAN, RASSF5, NORE1, RAPL. Potential tumor suppressor. Seems to be involved in lymphocyte adhesion by linking RAP1A activation upon T-cell receptor or chemokine stimulation to integrin activation. Isoform 2 stimulates lymphocyte polarization and the patch-like distribution of ITGAL/LFA-1, resulting in an enhanced adhesion to ICAM1. Together with RAP1A may participate in regulation of microtubule growth. The association of isoform 2 with activated RAP1A is required for directional movement of endothelial cells during wound healing. May be involved in regulation of Ras apoptotic function. The RASSF5-STK4/MST1 complex may mediate HRAS and KRAS induced apoptosis. Interacts directly with activated HRAS; a RASSF5-STK4/MST1 complex probably associates with activated HRAS (By similarity). Interacts with KRAS (By similarity). Probably interacts with Ras-like GTPases RRAS, MRAS, RAP1B, RAP2A and RALA (By similarity). Interacts with RRAS2 (PubMed:31130282). Can self-associate (By similarity). Interacts with RSSF1 isoform A (By similarity). The RSSF1 isoform A-RSSF5 heterodimer probably mediates the association of RSSF1 with HRAS (By similarity). Isoform 2 interacts with activated RAP1A and ITGAL/LFA-1 (PubMed:12845325, PubMed:15569673). Binds STK4/MST1, inhibiting STK4/MST1 autoactivation (PubMed:15109305).

EXTERNAL LINKS

RASSF5

Mutations

Mutation(s) distribution

Mutations table